Molecular Testing Labs
14401 SE. 1st St. Vancouver, WA 98684
Phone: 360-693-8850
CLIA# 50D2050397
Laboratory Director: Dr. Charles Sailey

Laboratory Testing Results			
Patient:	M[redacted]	DOB:	03[redacted]1977
Accession #:	UA00528923	Collection Date/Time:	02/01/2022 --:--
Sex at Birth:	Male	Received Date/Time:	02/08/2022 14:08
Provider:	Not Provided	Reported Date/Time:	02/11/2022 21:26

Sample Type: Urine	**Result**	**Reference Value**
Chlamydia trachomatis (CT):	Not Detected	*Not Detected*
Neisseria gonorrhea (NG):	Not Detected	*Not Detected*

Sample Type: Blood Card	**Result**	**Reference Value**
Creatinine (mg/dL):	1.17	*0.84 – 1.21*
Hepatitis B Surface Antigen (HBsAg):	Non-Reactive	*Non-Reactive*
Human Immunodeficiency Virus (HIV):	Non-Reactive	*Non-Reactive*

Sample Type: Oral Swab	**Result**	**Reference Value**
Chlamydia trachomatis (CT):	Not Detected	*Not Detected*
Neisseria gonorrhea (NG):	Not Detected	*Not Detected*

Sample Type: Anal Swab	**Result**	**Reference Value**
Chlamydia trachomatis (CT):	Not Detected	*Not Detected*
Neisseria gonorrhea (NG):	Not Detected	*Not Detected*

Creatinine: MTL recommends confirmatory testing with a different method for any abnormal result. Any abnormal result should be taken to your primary care provider for further analysis and treatment options. If you have an abnormal result for this test, the result should be viewed as a "presumptive" until a confirmatory test has been performed. An abnormal result may also be due to improper specimen collection. Creatinine testing was performed using LC-MS/MS. *

Hepatitis B Surface Antigen (HBsAg): The GS HBsAg Confirmatory Assay 3.0 is intended for qualitatively detecting the presence or absence of Hepatitis B surface antigen in human serum specimens. *

Human Immunodeficiency Virus (HIV): The GS HIV Combo Ag/Ab EIA is for the qualitative detection of HIV p24 antigen and antibodies to HIV Type 1 (HIV-1 groups M and O) and HIV Type 2 (HIV-2) in human blood. *

Roche cobas® CT/NG is an automated, qualitative in vitro nucleic acid diagnostic test, that utilizes real-time polymerase chain reaction (PCR), for the direct detection of *Chlamydia trachomatis* (CT) and/or *Neisseria gonorrhea* (NG) DNA in male and female urine, clinician-instructed self-collected vaginal swab specimens (collected in a clinical setting), and clinician-collected vaginal swab specimens, endocervical swab specimens, oropharyngeal (throat) swab specimens and anorectal swab specimens, and cervical specimens collected in PreservCyt® Solution. Molecular has validated this assay for home collection. This test is intended as an aid in the diagnosis of chlamydial and gonococcal disease in both symptomatic and asymptomatic individuals. *

* This test was developed and its performance characteristics determined by Molecular Testing Labs. This test has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This laboratory is regulated

Molecular Testing Labs
14401 SE. 1st St. Vancouver, WA 98684
Phone: 360-693-8850
CLIA# 50D2050397
Laboratory Director: Dr. Charles Sailey

under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity testing. Pursuant to the requirements of CLIA, this laboratory has established and verified this test's accuracy and precision.